Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May;19(5):44.
doi: 10.1007/s11886-017-0848-8.

Genetic Architecture of Familial Hypercholesterolaemia

Mahtab Sharifi  1   2 , Marta Futema  1 , Devaki Nair  2 , Steve E Humphries  3
Affiliations
Review

Genetic Architecture of Familial Hypercholesterolaemia

Mahtab Sharifi et al. Curr Cardiol Rep. 2017 May.

Abstract

Purpose of review: Familial hypercholesterolaemia (FH) is an inherited disorder of low-density lipoprotein cholesterol (LDL-C) which is characterised by a raised cholesterol level from birth and a high risk of premature coronary heart disease. In this paper, we review the genetic basis of FH and its impact on the clinical presentation.

Recent findings: Mutations in any of three genes (LDLR, APOB and PCSK9) are known to cause autosomal dominant FH, but a mutation can be found in only ∼40% of patients with a clinical diagnosis of FH. In the remainder, a polygenic aetiology is most likely, due to the co-inheritance of common LDL-C-raising variants. The cardiovascular presentation and management of FH will differ between patients based on their underlying genetic factors. New genotyping methods such as next-generation sequencing will provide us with better understanding of the genetic architecture of FH.

Keywords: APOB gene; Familial hypercholesterolaemia; LDLR gene; PCSK9 gene; Polygenic hypercholesterolaemia.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

Mahtab Sharifi declares that she has no conflict of interest.

Marta Futema reports speakers’ fees from Sanofi.

Devaki Nair has received grants from Pfizer (Pfizer Foundation award 2008), Solvay, Merck Sharp & Dohme, and Astra Zeneca. DN has advisory board membership with Merck Sharp & Dohme, Sanofi, Amgen and Astra Zeneca.

Steve E. Humphries is the Medical director of a UCL spin-out company StoreGene that offers to clinicians genetic testing for patients with familial hypercholesterolaemia.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Figures

Fig. 1
Fig. 1
Monogenic and polygenic causes of elevated plasma total cholesterol. Mutations that cause loss of function in LDLR or APOB or gain of function in PCSK9 result in an individual moving from a low point in the population cholesterol distribution to being over the diagnostic cut-off for familial hypercholesterolaemia (7.5 mmol/l). Mutations in PCSK9 are the most severe and in APOB, the mildest. The possibility that mutations in STAP1 may cause FH is shown. These individuals have ‘monogenic FH.’ It is also possible to have total cholesterol levels above the FH diagnostic cut-off by having inherited a greater than average number of common cholesterol-raising variants (SNP2, SNP2 etc) each of modest effect. As shown in (5), key SNPs are in LDLR, APOB, APOE (2×) ABCG8 and SORT1. These individuals have a ‘polygenic’ cause of their hypercholesterolaemia. In more than 80% of those with a clinical diagnosis of FH but with no detectable mutation in LDLR/APOB/PCSK9, the polygenic explanation is most likely. In the remainder, mutation in a novel gene may be present
See this image and copyright information in PMC

References

    1. Haralambos K, Whatley SD, Edwards R, Gingell R, Townsend D, Ashfield-Watt P, et al. Clinical experience of scoring criteria for familial hypercholesterolaemia (FH) genetic testing in Wales. Atherosclerosis. 2015;240(1):190–196. doi: 10.1016/j.atherosclerosis.2015.03.003. - DOI - PubMed
    1. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a huge prevalence review. Am J Epidemiol. 2004;160(5):407–420. doi: 10.1093/aje/kwh236. - DOI - PubMed
    1. DeMott KNL, Shaw EJ, Minhas R, Humphries SE, Kathoria M, Ritchie G, et al. Clinical guidelines and evidence review for familial hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners; 2008.
    1. Williams RR, Hunt SC, Schumacher MC, Hegele RA, Leppert MF, Ludwig EH, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol. 1993;72(2):171–176. doi: 10.1016/0002-9149(93)90155-6. - DOI - PubMed
    1. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat. 1992;1(6):445–466. doi: 10.1002/humu.1380010602. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources